Neurology
Cohort Study: Association of cumulative blood pressure with cognitive decline, dementia, and mortality.
25 Apr, 2022 | 00:35h | UTC
Anticholinergic medications and dementia: should we be worried?
25 Apr, 2022 | 00:14h | UTCCommonly-prescribed drugs and dementia: should we be worried? – Evidently Cochrane
Original Review:
Related:
How well do you know your anticholinergic (antimuscarinic) drugs? – Therapeutics Initiative
Anticholinergic drugs and risk of dementia: case-control study – The BMJ
Commentary on Twitter
Commonly-prescribed drugs & dementia: should we be worried? https://t.co/pvWxT6q48Z A @CochraneUK blog: Jodi Watt (a researcher @UofGlasgow) explores the @CochraneDCIG evidence on whether #anticholinergics might increase people’s risk of future memory problems, or even #dementia
— The Cochrane Library (@CochraneLibrary) April 22, 2022
Cohort Study: Assessment of a plasma amyloid probability score to estimate amyloid positron emission tomography findings among adults with cognitive impairment.
25 Apr, 2022 | 00:00h | UTC
Commentary on Twitter
This cohort study found a mass spectrometry-based blood test, measuring plasma Aβ42/40 & ApoE + age, accurately estimated brain amyloidosis via PET, and may help clinicians diagnose Alzheimer disease in patients with symptoms of cognitive impairment. https://t.co/VN7v0qf2uX
— JAMA Network Open (@JAMANetworkOpen) April 21, 2022
Cohort Study: Association of adverse childhood experiences with the development of multiple sclerosis.
24 Apr, 2022 | 23:54h | UTCNews Release: Childhood emotional trauma linked to heightened MS risk among women – BMJ Newsroom
UK drug regulator advises patients and doctors against the use of Pregabalin during pregnancy due to a possible increased risk of congenital malformations.
22 Apr, 2022 | 09:31h | UTCSee also: Pregabalin and risks in pregnancy – Medicines and Healthcare products Regulatory Agency
Source: Avoid prescribing pregabalin during pregnancy if possible, says UK drug regulator – The BMJ ($)
Commentary on Twitter
The Medicines and Healthcare Products Regulatory Agency (@MHRAgovuk) has strengthened its warning about avoiding pregabalin during pregnancy after new data showed an increased risk of major congenital malformations associated with the drug https://t.co/ghGvqCqA0C
— The BMJ (@bmj_latest) April 22, 2022
Retinal age gap as a predictive biomarker of future risk of Parkinson’s disease.
21 Apr, 2022 | 09:54h | UTCRetinal age gap as a predictive biomarker of future risk of Parkinson’s disease – Age and Ageing
Related: Retinal age gap as a predictive biomarker for mortality risk – British Journal of Ophthalmology (link to abstract – $ for full-text)
M-A: Association of immune checkpoint inhibitors with neurologic adverse events.
20 Apr, 2022 | 09:34h | UTCInvited Commentary: Neurological Toxic Effects Associated With Treatment With Immune Checkpoint Inhibitors—Are We Really Safer Now? – JAMA Network Open
Related:
Autoimmune Encephalitis Related to Cancer Treatment With Immune Checkpoint Inhibitors: Systematic Review – Neurology (link to abstract – $ for full-text)
Commentary on Twitter
Meta-analysis of 39 RCTs found immune checkpoint inhibitors have lower risk of neurological adverse effects compared to cytotoxic chemotherapy, but higher than placebo, across a range of malignancies. https://t.co/02GhICcu5H
— JAMA Network Open (@JAMANetworkOpen) April 19, 2022
Cohort Study: Association of subjective memory complaints with white matter hyperintensities and cognitive decline among older adults.
20 Apr, 2022 | 09:17h | UTCCommentary: Memory complaints associated with structural brain abnormalities and increased dementia risk – HealthImaging
Commentary on Twitter
In this cohort study, subjective memory complaints (SMCs) were associated with larger white matter hyperintensity volumes and faster cognitive decline, suggesting that SMCs are an important sign of cognitive impairment. https://t.co/mpCXDbylnf
— JAMA Network Open (@JAMANetworkOpen) April 15, 2022
Video: Here’s what we know about COVID-19’s impact on the brain.
19 Apr, 2022 | 02:22h | UTCHere’s what we know about COVID-19’s impact on the brain – Science
Related:
SARS-CoV-2 is associated with changes in brain structure in UK Biobank – Nature
Nervous system consequences of COVID-19 – Science
The COVID generation: how is the pandemic affecting kids’ brains? – Nature
Assessment of Cognitive Function in Patients After COVID-19 Infection – JAMA Network Open
M-A: Global prevalence of post COVID-19 condition or long COVID.
19 Apr, 2022 | 02:18h | UTCCommentary: Global data reveal half may have long COVID 4 months on – CIDRAP
Commentary on Twitter (thread – click for more)
🚨The so far largest meta-analysis of more than 1.5 million infected individuals puts the global prevalence of #LongCovid at 43%. Some additional key findings. 🧵https://t.co/XGu23MV3Ra
1/— Jonas R. Kunst (@kunstjonas.bsky.social) (@KunstJonas) April 17, 2022
Cohort Study: Association of treatment with antipsychotics, antidepressants, or both with movement disorders and seizures among children and adolescents with depression.
19 Apr, 2022 | 01:50h | UTC
Commentary on Twitter
In this cohort study, adjunctive antipsychotics with antidepressants were associated with movement disorders and seizures compared with antidepressant monotherapy in children and adolescents with depression. https://t.co/3SVKEThwkR
— JAMA Network Open (@JAMANetworkOpen) April 15, 2022
Palliative care for older people with dementia—we need a paradigm shift in our approach – “Advance care planning (ACP) is a central tenet of good dementia palliative care”.
19 Apr, 2022 | 01:30h | UTC
RCT: Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder.
19 Apr, 2022 | 01:20h | UTCSafety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial – The Lancet Neurology (link to abstract – $ for full-text)
A randomized controlled trial explored the safety and tolerability of Sulthiame in sleep apnea.
18 Apr, 2022 | 10:08h | UTCNews Release: Drug reduced frequency of breathing pauses in sleep apnea – University of Gothenburg
Commentary on Twitter
In a four-week trial of patients with OSA not tolerating PAP therapy, researchers found that the carbonic anhydrase inhibitor sulthiame reduced OSA by more than 20 events per hour, one of the strongest reductions reported in a drug trial in OSA. https://t.co/EizlbFbvFm pic.twitter.com/DxylRQR4Pa
— American Academy of Sleep Medicine (@AASMorg) February 28, 2022
The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates.
18 Apr, 2022 | 10:03h | UTCNews Release: Global estimates of headaches suggest disorder impacts over 50 percent of the population – BMC
Cross-sectional study: The use of Selective Serotonin Reuptake Inhibitors is associated with a reduction in measured movements.
14 Apr, 2022 | 08:32h | UTC
Commentary on Twitter
This cross-sectional study found SSRI use was associated with a reduction in measured movements, highlighting the utility of passively collected data for exploring and characterizing adverse drug effects. https://t.co/54ZngDdt8u
— JAMA Network Open (@JAMANetworkOpen) April 7, 2022
Population based cohort study: Healthy lifestyle and life expectancy with and without Alzheimer’s dementia.
14 Apr, 2022 | 08:27h | UTCEditorial: Healthy lifestyles and more life years without dementia – The BMJ
Commentary on Twitter
A new US study suggests that a healthy lifestyle is associated with a longer life expectancy among both men and women, and they lived a larger proportion of their remaining years without Alzheimer’s diseasehttps://t.co/eXsQRd6mon
— The BMJ (@bmj_latest) April 14, 2022
New insights into the genetic etiology of Alzheimer’s disease and related dementias.
13 Apr, 2022 | 10:26h | UTCNews Release:
Commentaries:
42 previously unknown genes discovered for Alzheimer’s disease – CNN
Alzheimer’s disease research takes ‘major leap forward’ – BBC
Commentary on Twitter
A meta-analysis in @NatureGenet of genome-wide association studies on Alzheimer’s disease and related dementias identifies new loci and enables generation of a new genetic risk score associated with the risk of future Alzheimer’s disease and dementia. https://t.co/EAtdlRozld pic.twitter.com/5rtWWt4HyS
— Nature Portfolio (@NaturePortfolio) April 11, 2022
Pre-hospital and emergency department treatment of convulsive status epilepticus in adults: an evidence synthesis.
13 Apr, 2022 | 10:15h | UTC
RCT: Efficacy and safety of AbobotulinumtoxinA in patients with neurogenic detrusor overactivity incontinence performing regular clean intermittent catheterization.
12 Apr, 2022 | 08:42h | UTC
M-A: Association of olfactory impairment with all-cause mortality.
11 Apr, 2022 | 01:01h | UTCAssociation of Olfactory Impairment With All-Cause Mortality: A Systematic Review and Meta-analysis – JAMA Otolaryngology-Head & Neck Surgery (free for a limited period)
Invited Commentary: Olfactory Impairment and Mortality—Is Smell Loss Deadly? – JAMA Otolaryngology-Head & Neck Surgery (free for a limited period)
Commentary on Twitter
Metaanalysis found that #olfactory impairment was associated with 52% higher all-cause #mortality, after adjustment for demographics & comorbidities. The ability to smell is an important marker of general health and biological aging. https://t.co/XEhSpjO2hZ @BenjaminKJTan @mysgh
— JAMA Otolaryngology – Head & Neck Surgery (@JAMAOto) April 7, 2022
M-A: Prophylactic therapies for morbidity and mortality after aneurysmal subarachnoid hemorrhage.
11 Apr, 2022 | 00:52h | UTCProphylactic Therapies for Morbidity and Mortality After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Network Meta-Analysis of Randomized Trials – Stroke (link to abstract – $ for full-text)
Commentary on Twitter
Prophylactic Therapies for Morbidity and Mortality After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Network Meta-Analysis of Randomized Trials #stroke #AHAJournals https://t.co/GkM5GlFBd7 pic.twitter.com/6ipIaUK5KX
— Stroke AHA/ASA (@StrokeAHA_ASA) April 8, 2022
Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial.
11 Apr, 2022 | 00:50h | UTCOriginal Study: Randomized Trial: Effects of Aspirin for Primary Prevention in Persons with Diabetes
Commentary on Twitter (images under a https://creativecommons.org/licenses/by/4.0/ license)
Does aspirin have an effect on dementia and cognitive function? Discover it in the EHJ!https://t.co/u5X1fxrULk#aspirin #dementia #CVD #ASCEND #trial #diabetes #cardiotwitter @escardio @ESC_Journals pic.twitter.com/TyrnUnf0MN
— EHJ Editor-in-Chief (@ehj_ed) April 8, 2022
State of the Art Review: Prognostication and shared decision making in neurocritical care.
8 Apr, 2022 | 10:53h | UTCPrognostication and shared decision making in neurocritical care – The BMJ
Commentary on Twitter
It's out TODAY: Thank you @bmj_latest for this opportunity as an invited 'State of the Art Review'💥 on such an important topic‼️ Great job @K_Goostrey 👏👏. Proud of this product: 👉Prognostication and Shared Decision Making in #NCC https://t.co/VeFUlRe0xG @UMassChanNeuro
— S Muehlschlegel MD MPH, FNCS, FCCM, FAAN (@SMuehlschMD) April 7, 2022
Review | Chronic pain and infection: mechanisms, causes, conditions, treatments, and controversies.
8 Apr, 2022 | 10:27h | UTC